Aventis Arava hepatotoxicity
Executive Summary
Aventis alerts physicians to Arava (leflunomide) hepatotoxicity labeling revisions for the rheumatoid arthritis agent in "Dear Doctor" letter. The changes, which include a severe liver injury warning and more specific liver function monitoring directions, were added to labeling this summer (1"The Pink Sheet" June 23, 2003, p. 7)...
You may also be interested in...
Aventis Arava Adds Physical Function Claim, Bolded Liver Safety Warning
Arava labeling has been updated to include more explicit liver function monitoring directions
Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.